CytoDyn (STU:296) ROE % Adjusted to Book Value: 0.00% (As of Feb. 2026)

CytoDyn STU:296 +3.13% 28 ROE % Adjusted to Book Value is 0.00% as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

CytoDyn's ROE % for the quarter that ended in Feb. 2026 was 0.00%. CytoDyn's PB Ratio for the quarter that ended in Feb. 2026 was N/A. CytoDyn's ROE % Adjusted to Book Value for the quarter that ended in Feb. 2026 was N/A.

CytoDyn ROE % Adjusted to Book Value Related Terms

CytoDyn ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for CytoDyn's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn ROE % Adjusted to Book Value Chart

CytoDyn Annual Data

Trend

May16

May17

May18

May19

May20

May21

May22

May23

May24

May25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.00

Negative Equity

CytoDyn Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

STU:296 vs VSTM, IRD, PALI: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, CytoDyn's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CytoDyn's ROE % Adjusted to Book Value falls into.

Save Embed

28GF Score

CytoDyn Inc STU:296

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CytoDyn ROE % Adjusted to Book Value Calculation

CytoDyn's ROE % Adjusted to Book Value for the fiscal year that ended in May. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

CytoDyn's ROE % Adjusted to Book Value for the quarter that ended in Feb. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 0.00% mean?

CytoDyn (STU:296) has a ROE % Adjusted to Book Value of 0.00% as of Feb. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CytoDyn and its competitors.

Is CytoDyn's ROE % Adjusted to Book Value too high?

CytoDyn's current ROE % Adjusted to Book Value is 0.00%. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does CytoDyn's ROE % Adjusted to Book Value compare to VSTM and IRD?

CytoDyn's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CytoDyn and its competitors. CytoDyn's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CytoDyn stock overvalued right now?

CytoDyn (STU:296) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For CytoDyn (STU:296), the current ROE % Adjusted to Book Value is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Industry Healthcare Biotechnology

Comparable Companies VSTM IRD PALI PRLD GALT DMAC RCKT ABEO TENX LCTX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CYDY:USA

Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website https://www.cytodyn.com

CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

28GF Score

Get the complete analysis for STU:296

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20

Price

View STU:296 Analysis

See ROE % Adjusted to Book Value data for all stocks →